QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
NASDAQ:RIGL

Rigel Pharmaceuticals - RIGL Stock Forecast, Price & News

$1.56
0.00 (0.00%)
(As of 08/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.53
$1.61
50-Day Range
$0.67
$1.56
52-Week Range
$0.64
$4.24
Volume
2.57 million shs
Average Volume
3.74 million shs
Market Capitalization
$269.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.46

Rigel Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.29 Rating Score
Upside/​Downside
68.3% Upside
$2.63 Price Target
Short Interest
Healthy
6.28% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.72mentions of Rigel Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$690,000 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.52) to ($0.36) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.45 out of 5 stars

Medical Sector

242nd out of 1,124 stocks

Pharmaceutical Preparations Industry

108th out of 555 stocks

RIGL stock logo

About Rigel Pharmaceuticals (NASDAQ:RIGL) Stock

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Analysts Set New Price Targets

A number of brokerages have issued reports on RIGL. Jefferies Financial Group downgraded shares of Rigel Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Wednesday, June 8th. Piper Sandler downgraded shares of Rigel Pharmaceuticals from an "overweight" rating to a "neutral" rating and reduced their price target for the company from $7.00 to $1.00 in a research note on Wednesday, June 8th. B. Riley reduced their price target on shares of Rigel Pharmaceuticals from $4.00 to $1.25 and set a "neutral" rating on the stock in a research note on Thursday, June 9th. HC Wainwright reduced their price target on shares of Rigel Pharmaceuticals from $11.00 to $7.00 and set a "buy" rating on the stock in a research note on Wednesday, June 8th. Finally, Cantor Fitzgerald downgraded shares of Rigel Pharmaceuticals from an "overweight" rating to a "neutral" rating and reduced their price target for the company from $6.00 to $1.00 in a research note on Wednesday, June 8th. Six equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, Rigel Pharmaceuticals presently has an average rating of "Hold" and an average target price of $2.46.

Rigel Pharmaceuticals Price Performance

NASDAQ:RIGL remained flat at $1.56 during mid-day trading on Tuesday. 2,568,170 shares of the company traded hands, compared to its average volume of 3,743,337. The stock's fifty day moving average is $1.21 and its 200 day moving average is $2.11. The company has a debt-to-equity ratio of 4.39, a current ratio of 2.19 and a quick ratio of 2.08. Rigel Pharmaceuticals has a twelve month low of $0.64 and a twelve month high of $4.24.

Insider Buying and Selling

In other Rigel Pharmaceuticals news, CEO Raul R. Rodriguez bought 1,000,000 shares of the business's stock in a transaction that occurred on Thursday, June 9th. The shares were acquired at an average cost of $0.69 per share, for a total transaction of $690,000.00. Following the transaction, the chief executive officer now directly owns 1,391,776 shares in the company, valued at $960,325.44. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 6.43% of the stock is owned by corporate insiders.

Receive RIGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rigel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RIGL Stock News Headlines

27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile. Take your trading to the next level with the Options Strategy Guide. pixel
Rigel Pharmaceuticals Inc. Q2 Loss beats estimates
Earnings Outlook For Rigel Pharmaceuticals
Expert Ratings for Rigel Pharmaceuticals
Rigel Pharmaceuticals Q1 2022 Earnings Preview
See More Headlines
Receive RIGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rigel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RIGL Company Calendar

Last Earnings
11/02/2021
Today
8/16/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:RIGL
CUSIP
76655960
Employees
165
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$2.63
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+57.6%
Consensus Rating
Hold
Rating Score (0-4)
2.29
Research Coverage
7 Analysts

Profitability

Net Income
$-17,910,000.00
Pretax Margin
-95.73%

Debt

Sales & Book Value

Annual Sales
$149.24 million
Book Value
$0.18 per share

Miscellaneous

Free Float
161,723,000
Market Cap
$269.62 million
Optionable
Optionable
Beta
1.63

Social Links


Key Executives

  • Mr. Raul R. Rodriguez (Age 61)
    Pres, CEO & Director
    Comp: $979.34k
  • Mr. Dean L. Schorno CPA (Age 59)
    Exec. VP & CFO
    Comp: $623.46k
  • Ms. Dolly A. Vance (Age 57)
    Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec.
    Comp: $810.06k
  • Dr. Wolfgang Dummer M.D. (Age 56)
    Ph.D., Exec. VP & Chief Medical Officer
    Comp: $644.05k
  • Mr. David A. Santos (Age 59)
    Exec. VP & Chief Commercial Officer
    Comp: $600.64k
  • Mr. Joseph Lasaga (Age 47)
    Exec. VP of Corp. Devel.
  • Ms. Julie Patel
    Sr. VP of HR
  • Dr. Esteban S. Masuda (Age 60)
    Exec. VP of Research
  • Mr. Tarek Sallam
    VP of Marketing













RIGL Stock - Frequently Asked Questions

Should I buy or sell Rigel Pharmaceuticals stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last twelve months. There are currently 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" RIGL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RIGL, but not buy additional shares or sell existing shares.
View RIGL analyst ratings
or view top-rated stocks.

What is Rigel Pharmaceuticals' stock price forecast for 2022?

7 equities research analysts have issued twelve-month target prices for Rigel Pharmaceuticals' shares. Their RIGL share price forecasts range from $1.00 to $7.00. On average, they anticipate the company's stock price to reach $2.63 in the next year. This suggests a possible upside of 68.3% from the stock's current price.
View analysts price targets for RIGL
or view top-rated stocks among Wall Street analysts.

How have RIGL shares performed in 2022?

Rigel Pharmaceuticals' stock was trading at $2.65 at the beginning of the year. Since then, RIGL stock has decreased by 41.1% and is now trading at $1.56.
View the best growth stocks for 2022 here
.

When is Rigel Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our RIGL earnings forecast
.

How were Rigel Pharmaceuticals' earnings last quarter?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) issued its earnings results on Tuesday, November, 2nd. The biotechnology company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by $0.02. The biotechnology company had revenue of $21.54 million for the quarter, compared to analyst estimates of $24.16 million. Rigel Pharmaceuticals had a negative net margin of 95.51% and a negative trailing twelve-month return on equity of 406.57%. During the same period last year, the firm earned ($0.08) earnings per share.

What is Raul Rodriguez's approval rating as Rigel Pharmaceuticals' CEO?

6 employees have rated Rigel Pharmaceuticals Chief Executive Officer Raul Rodriguez on Glassdoor.com. Raul Rodriguez has an approval rating of 84% among the company's employees.

What other stocks do shareholders of Rigel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Aeterna Zentaris (AEZS), KushCo (KSHB), Novan (NOVN), Bionano Genomics (BNGO), OrganiGram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).

What is Rigel Pharmaceuticals' stock symbol?

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

Who are Rigel Pharmaceuticals' major shareholders?

Rigel Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (13.96%), State Street Corp (13.85%), Tamarack Advisers LP (1.16%), Assenagon Asset Management S.A. (0.96%), Northern Trust Corp (0.95%) and CM Management LLC (0.75%).
View institutional ownership trends
.

How do I buy shares of Rigel Pharmaceuticals?

Shares of RIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rigel Pharmaceuticals' stock price today?

One share of RIGL stock can currently be purchased for approximately $1.56.

How much money does Rigel Pharmaceuticals make?

Rigel Pharmaceuticals (NASDAQ:RIGL) has a market capitalization of $269.62 million and generates $149.24 million in revenue each year. The biotechnology company earns $-17,910,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis.

How many employees does Rigel Pharmaceuticals have?

The company employs 165 workers across the globe.

When was Rigel Pharmaceuticals founded?

Rigel Pharmaceuticals was founded in 1996.

How can I contact Rigel Pharmaceuticals?

Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.rigel.com. The biotechnology company can be reached via phone at (650) 624-1100, via email at ir@rigel.com, or via fax at 650-624-1101.

This page (NASDAQ:RIGL) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.